CytRx Corporation (Nasdaq: CYTR) announced that it has selected its next drug, designated DK049, for clinical development in 2016 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE